March 21, 2018
1 min read
Save

FDA approves Ilumya for moderate-to-severe plaque psoriasis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Today, Sun Pharma announced that Ilumya has been approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy.

“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” Abhay Gandhi, president and CEO of the North American division of Sun Pharma, said in a press release. “We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis.”

The FDA approval of Ilumya (tildrakizumab-asmn, Sun Pharma) is based on data from two phase 3 multicenter, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), according to the release. The studies evaluated the efficacy of tildrakizumab-asmn in 926 adults with moderate-to-severe plaque psoriasis compared with placebo.

At week 28, most participants (74%) achieved 75% skin clearance with three doses of 100 mg of tildrakizumab-asmn, according to the release. At week 64, 75% skin clearance was maintained by 84% of patients who continued taking tildrakizumab-asmn compared with 22% of patients re-randomized to placebo, according to the release.

A Physician’s Global Assessment score of “clear” or “minimal” was maintained at week 64 in 69% of patients receiving tildrakizumab-asmn who achieved the score at week 28, compared with 14% of those who were re-randomized to receive placebo, according to the release.

In patients who showed prior severe hypersensitivity reaction to tildrakizumab or any of the excipients, tildrakizumab-asmn was contraindicated, according to the release.

“Now that Ilumya is approved, we are currently working closely with Merck and the FDA to complete the post-approval commitments,” Sun Pharma told Healio Internal Medicine. “Once this step is complete, we will have a better understanding of when the product will be available for patients.”